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Changes in microRNAs (miRNAs) expression in many types of cancer suggest that they
may be involved in crucial steps during tumor progression. Indeed, miRNAs deregulation
has been described in pituitary tumorigenesis, but few studies have described their role
in pituitary tumor progression toward aggressiveness and malignancy. To assess the role
of miRNAs within the hierarchical cascade of events in prolactin (PRL) tumors during
progression, we used an integrative genomic approach to associate clinical–pathological
features, global miRNA expression, and transcriptomic profiles of the same human
tumors. We describe the specific down-regulation of one principal miRNA, miR-183, in
the 8 aggressive (A, grade 2b) compared to the 18 non-aggressive (NA, grades 1a, 2a)
PRL tumors. We demonstrate that it acts as an anti-proliferative gene by directly targeting
KIAA0101, which is involved in cell cycle activation and inhibition of p53–p21-mediated
cell cycle arrest. Moreover, we show that miR-183 and KIAA0101 expression significantly
correlate with the main markers of pituitary tumors aggressiveness, Ki-67 and p53. These
results confirm the activation of proliferation in aggressive and malignant PRL tumors
compared to non-aggressive ones. Importantly, these data also demonstrate the ability
of such an integrative genomic strategy, applied in the same human tumors, to identify
the molecular mechanisms responsible for tumoral progression even from a small cohort
of patients.
Keywords: pituitary tumor, PRL tumor, miRNA, integrative genomics, aggressiveness, malignancy
Introduction
Endocrine pituitary tumors are someof themost frequent intracranial tumors, and are generally con-
sidered benign. Nevertheless,many of these tumors (30–45%) are invasive (1) and some are clinically
aggressive with recurrences and resistance to medical treatment (2, 3). In 2004, the World Health
Organization (WHO) classification identified the “atypical adenoma” with “uncertain malignancy”
(4). Only tumors with metastasis were considered malignant. Our group previously studied tumor
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progression in prolactin (PRL) tumors, which have been charac-
terized clinically, histologically, molecularly, and genetically (5–
7). Recently, a new classification of the five immunohistochemical
(IHC) types of pituitary tumors (GH, PRL, ACTH, FSH-LH, and
TSH) has been proposed, which introduces a grading that takes
the invasion and the proliferation into account (7). However,
the molecular events responsible for tumor progression from an
aggressive to malignant phenotype remain unknown.
Transcriptomic studies comparing all types of pituitary tumors
to normal pituitary have highlighted different deregulated genes
and pathways [reviewed in Ref. (8)]. However, as all tumor types
were combined, the comparison of gene expression was able to
decipher mechanisms involved in tumorigenesis, but not those
specifically involved in progression. A recent study coupling tran-
scriptomic and DNA copy number analyses performed on one
subtype of pituitary tumor, PRL tumors, has revealed the dereg-
ulation of genes connected in a specific signaling pathway that
controls cell proliferation, as well as an allelic loss on chromosome
11 specifically associated with aggressiveness and malignancy (5,
6, 8, 9). Nevertheless, the driving role of these alterations during
progression toward aggressiveness is still unknown.
To decipher the driving event(s) leading to aggressive and
malignant phenotypes of PRL tumors, we explored the global
alterations of microRNAs (miRNAs) expression. miRNAs are a
class of small non-coding RNAs, between 21 and 25 nt in length,
involved in post-transcriptional regulation of gene expression
(10). They act by binding to 30-untranslated regions (30-UTR)
of target mRNAs, causing inhibition of translation or mRNA
degradation (10). Several studies have shown that miRNAs are
deregulated in many types of cancer and act as tumor suppressors
or oncogenes depending on the function of the targeted genes
[for review, see Ref. (11, 12)]. Moreover, miRNAs seem to be
involved in the regulation of many steps of tumor progression (12,
13) that are defined as hallmarks of cancer (chronic proliferation,
resistance to cell death, unlimited replicative potential, induction
of angiogenesis, invasion, and metastasis) (14).
Many studies have explored the role of miRNAs in pituitary
tumorigenesis by comparing tumoral to normal pituitary [Table
S1 in Supplementary Material; (15–29)]. To our knowledge, how-
ever, only one study has explored the alteration of miRNAs
malignancy (21).
In this study, we have performed a genome-wide analysis of
miRNAexpression in the samenon-aggressive and aggressive PRL
tumor samples as those used in earlier analyses (5, 9). Further,
we propose a strategy of data filtering to find candidate miR-
NAs involved in tumor progression toward aggressiveness and
malignancy.
Materials and Methods
Patients and Tumors Characteristics
The 26 patients, 13 males and 13 females presenting with hyper-
prolactinemia without acromegaly, underwent surgery for pitu-
itary tumors. None were operated under dopamine agonist treat-
ment at the time of operation. Twenty-five patients were part of
the Hypopronos cohort, previously published in Ref. (6, 7, 9). By
histology, all the tumors were sparsely granulated and expressed
PRL in almost all cells. Taking into account the invasion of the
cavernous or the sphenoid sinus by MRI and the three mark-
ers of the cell cycle (mitoses, Ki-67, and p53), the tumors were
classified into five grades (1a: non-invasive; 1b: non-invasive and
proliferative; 2a: invasive; 2b: invasive and proliferative; and 3:
malignant) (7) and split into two groups, non-aggressive (grades
1a; 2a; n= 18) or aggressive (grade 2b; n= 8), according to the
pathological classification and clinical behavior during follow-up.
Three tumors (#3, #4, and #5) were considered malignant and
classified as grade 3 based on the occurrence of metastasis during
follow-up. The main clinical and pathological data are shown in
Table 1. For all tumors, fragments were immediately frozen in
liquid nitrogen after verification by the pathologist, and kept at
 80° until molecular analysis. The same tumors have been used
for different molecular analyses (microarrays, PCR, and CGH)
recently published by our group (5–7, 9, 30).
The study was approved by the ethics committee of Lyon,
and informed consent was obtained for each patient according
to French law. This authorization was given in the context of a
larger French clinical study named HYPOPRONOS (Programme
Hospitalier de Recherche Clinique National 27-43).
Isolation of Total RNA
Total RNA from pituitary tumors and normal pituitary was
extracted using the miRNeasy Mini kit with DNase treatment
(Qiagen, Venlo, Netherlands) according to the manufacturer’s
protocol. Total RNA from cell lines was extracted usingmiRNeasy
Micro kit with DNase treatment (Qiagen) according to the manu-
facturer’s protocol. Total RNA yield was measured by OD260 and
the purity confirmed by reaching anA260/A280 ratio of 1.9:2.1 on
a Nanodrop ND-1000. The quality was evaluated on nanochips
with an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA) according to the manufacturer’s protocol.
miRNA Microarray Processing and Analysis
Global miRNA expression was assessed in 12 of 26 PRL tumors
(8 non-aggressive and 4 aggressive) (Table 1, tumors in bold)
using Human miRNAMicroarray v3, 8 15k from Agilent Tech-
nologies. Microarrays were processed as described in the miRNA
Microarray System with miRNA Complete Labeling and Hyb Kit
version 2.4 September 2011 (available at http://www.genomics.
agilent.com). Microarrays were scanned on an Agilent Scanner
Type C. Data were extracted using Agilent feature extraction
software 10.7. Data files (.txt) from Feature Extraction and then
were normalized using spikes in Genespring Software 7.0 (Agilent
Technologies). Statistical analysis was performed using Gene-
spring software 7.0 to isolate differentially expressed miRNAs in
aggressive–invasive vs. non-aggressive tumors. A miRNA tran-
script was considered differentially expressed if the difference
gave a p-value 0.05 in the Welch ANOVA parametric test, and
showed a minimal 1.5 fold variation. Data are available on the
GEO database under the accession number GSE46294. Some of
these tumors were previously analyzed for transcriptomic profil-
ing in Ref. (9).
TaqMan Low Density Array Analysis
TaqMan Low Density Array (Applied Biosystems, Carlsbad, CA,
USA) allowed testing of a large subset of miRNAs by RT-qPCR
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TABLE 1 | Clinical and pathological data in 26 patients operated for PRL tumors.
Tumor
number
Sex Age Preoperative
PRL plasma level
Tumor
size
Invasion Ki-67% P53% Tumor
gradesa
Groupsb Postoperative events
1* M 66 2610 Macro Yes 8 3 2b A Recurrence, death
2* F 54 440 Macro Yes 4 1.3 2b A Recurrence
3* M 68 4170 Macro Yes 10 2.3 2b** A Recurrence, metastasis, death
4* M 54 400 Macro Yes 20 1 2b** A Recurrence, metastasis, death
5* F 31 3000 Macro Yes 30 10 2b** A Recurrence, metastasis, death
6* F 43 150 Macro Yes 2.7 0.5 2b A Recurrence
25 M 60 690 Giant Yes 3.6 2.6 2b A Recurrence
26 M 53 320 Macro Yes 5.5 2 2b A Recurrence
7* M 40 1700 Macro Yes 0 0 2a NA Persistence
8* M 42 1540 Micro Yes 1.8 0 2a NA Persistence
9* M 42 700 Macro No 0 0 1a NA Remission
10* F 44 100 Micro No 0 0 1a NA Remission
11* M 39 4080 Giant No 1.3 0 1a NA Remission
12* F 30 97 Micro No 0 0 1a NA Remission
13 F 21 900 Macro No 0 0 1a NA Remission
14 F 28 80 Micro No 0 0 1a NA Remission
15 F 36 120 Macro No 0 0 1a NA ND
16 F 25 120 Micro No 0 0 1a NA Remission
17 F 55 860 Macro No 0 0 1a NA Remission
18 F 26 300 Micro No 0 0 1a NA Remission
19 M 26 180 Macro Yes 0.5 1 2a NA Recurrence
20 F 38 105 Micro Yes 0 0 2a NA Recurrence
21 M 27 1000 Giant Yes 0 0 2a NA Persistence
22 M 52 810 Macro Yes 0 0 2a NA Persistence
23 F 73 ND Macro Yes 0 0 2a NA ND
24 M 45 1000 Giant Yes 0 0 2a NA Persistence
*Tumors used for CGH and transcriptomic profiling in Wierinckx et al. (9); tumors in bold used for miRnome analysis.
**These tumors were grade 2b at the first surgery, and became grade 3 because metastasis appeared during follow-up
aClassification of the tumors according to Trouillas et al. (7).
bTumors split in two groups: aggressive (A) and non-aggressive (NA) according to Wierinckx et al. (9).
in a single assay. Briefly, 500 ng of total RNA was used for cDNA
synthesis with the TaqMan microRNA Reverse Transcription kit
according to the manufacturer’s protocol. Then, miRNA expres-
sion analysis was performed by Real-Time PCR using the Taq-
Man MicroRNA Array (Applied Biosystems) according to the
manufacturer’s protocol and run on a 7900HT Fast Real-Time
PCR System (Applied Biosystems). Threshold cycle (Ct) values
provided an index of miRNA level. The level of miRNA RNU6
was used as an internal standard. Values were obtained using
RQ Manager Software for analysis (Applied Biosystems) and the
detection limit was 32Ct. Comparison between samples was made
using Genespring software 7.0 (Agilent Technology).
miRNA RT-qPCR
Single miRNA expression was assessed in cell lines and 26
PRL tumors (18 non-aggressive and 8 aggressive tumors) using
TaqMan microRNA assays (Applied Biosystems). Assays with
the following identification numbers were used in this study:
miR-183 no. 002269; miR-let-7g no. 002282; and RNU6B no.
001093. Briefly, RT primers were multiplexed to obtain mixed RT
primers at 62.5 nM each. Then, 40 ng of total RNA was reverse-
transcribed using the TaqManmicroRNA reverse transcription kit
(Applied Biosystems) with the following modifications: primers
at a 12.5 nM final concentration, dNTP at 2 nM final concentra-
tion, 100U of MultiScribe Reverse Transcriptase per reaction, RT
Buffer 1 final concentration, and 5U of RNase inhibitor per
reaction. The RT program used was 30min at 16°C, 30min at
42°C, and 5min at 85°C. mRNA levels were analyzed by qPCR
using TaqMan small RNA assays at 1 final concentration and
TaqMan Universal PCR Master Mix II No UNG at 0.5 final
concentration, run on a 7900HT Fast Real-Time PCR Systemwith
the following cycle: standard mode, 10min at 95°C then 40 cycles
of denaturation at 95°C for 15 s and hybridization and elongation
at 60°C for 60 s. Relative miRNA expression was measured using
hsa-let-7g (shown to be constant among tumors by microarray)
and RNU6B as a reference with RQ Manager Software (Applied
Biosystems).
Gene Expression Analysis
Five hundred nanograms of total RNA were reverse-transcribed
using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA) following the manufacturer’s protocol. The cDNA synthe-
sized was measured by RT-qPCR using FAST SYBR GreenMaster
Mix (Applied Biosystems) following the manufacturer’s recom-
mendations. The PCR program was as follows: 95°C for 20 s then
40 cycles of denaturation at 95°C for 1 s and hybridization and
elongation at 60°C for 20 s on a 7900HT Fast Real-Time PCR
System. Relative expression analysis was performed using RQ
Manager Software (Applied Biosystems) with the RPL4 gene as
a reference. Primers were designed using the NCBI Primer-Blast
algorithm. All primers are listed in Table S2 in Supplementary
Material.
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Cell Culture and Transfection
HeLa cells (high proliferating rate) were cultured in DMEM
with 10% FBS and 1% penicillin/streptomycin (PS). ZR-75-1
cells (mammary epithelial cancer cell line, low proliferating rate)
were cultured in RPMI with 10% FBS, 1% Pyruvate, and 1%
PS. Transfection of pre-miR miRNA precursor (Ambion for Life
Technologies) was performed using 100 nM final concentration of
pre-miRNA precursor with SiPORT NeoFX Transfection Agent
(Ambion) following the manufacturer’s instructions. Three pre-
miRNA precursors were used: hsa-pre-miR-183 (PM10426), the
positive control hsa-pre-miR-1 (AM17150), and the negative con-
trol pre-miR miRNA precursor negative control #1 (AM17110).
Transfections of plasmids were performed using FuGENE® 6
Transfection Reagent (Promega) following the manufacturer’s
instructions.
Plasmids and Constructs
The human pre-mRNA expression construct lenti-miR-183
(MI0000273) and scramble control hairpin in pCDH-CMV-
MCS-EF1-copGFP (CD511B-1) were purchased from System
Biosciences (SBI, Mountain View, CA, USA). A pcDNA3 plasmid
containing ETS2-flag purchased from Addgene (31) was used to
express ETS2, with an empty pcDNA3 as a control. Following the
supplier’s instructions, the pmirGLO Dual-Luciferase miRNA
Target Expression Vector (Promega, Madison, WI, USA) was
used to measure the activity of miR-183 matching the target
sequence in KIAA0101; sequences were cloned into the 30-UTR
of luciferase (sense, 50-AAACTAGCGGCCGCTTTGATTATTG
GAATGGTGCCATATTGT-30; antisense, 30-TTTGATCGCCGG
CGAAACTAATAACCTTACCACGGTATAACAGATC-50), and
with mismatch sequence within the seed (sense, 50-AAACTAG
CGGCCGCTTTGATTATTGGAATGGTAAATATTGT-30; anti-
sense, 30-TTTGATCGCCGGCGAAACTAATAACCTTACCATT
TTATAACAGATC-50).
Protein Expression Analysis
Cells were lysed in RIPA buffer supplemented with a complete
protease inhibitor cocktail (Roche). Protein expression was exam-
ined by western blot using mouse monoclonal anti-KIAA0101 ab
56773 (Abcam, Cambridge, UK), rabbit polyclonal anti-ETS2 sc-
351 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and mon-
oclonal anti-β-actin clone AC-15 (Sigma Aldrich, St Louis, MO,
USA) antibodies for primary detection. Horseradish peroxidase-
conjugated rabbit anti-mouse and goat anti-rabbit polyclonal sec-
ondary antibodies (Dako, Denmark) were used. Western blots
were developed using Luminol (Santa Cruz Biotechnology).
Proliferation and Cell Cycle Assay
Growth curves were performed by daily counting of viable pre-
miR-183 transfected and scramble transfected cells expressing
GFP protein using an LSRII FACS flow cytometer (BDBiosciences
Europe, Erembodegem, Belgium). For cell cycle distributions, pre-
miR-183 transfected and scramble transfected cells were collected
and incubated 1 h at 4°C with propidium iodide (0.05mg/ml)
solution containing Non-idet-P40 (0.05%) for proliferation and
cell cycle assays. Cells were analyzed using a FACSCalibur flow
cytometer (BD Biosciences Europe, Erembodegem, Belgium) and
cell cycle distribution was determined using Modfit LT 2.0™
software (Veritysoftware Inc., Topsham, ME, USA). BrdU incor-
poration assays were performed using the APC-BrdU flow kit (BD
Pharmingen), following the manufacturer’s protocol.
Chromatin Immunoprecipitation Assays
HeLa cellswere fixed inmediumwith 1% formaldehyde for 20min
and then harvested in SDS lysis buffer (50mM Tris HCl pH
8.1, 10mM EDTA, and 1% SDS) with added protease inhibitors.
Chromatin was then sonicated using 25 cycles of 30 s ON/OFF
on a Diagenode UCD-300 sonicator. Sheared chromatin was
pre-cleared using sepharose beads (Sigma Aldrich) followed by
overnight incubation with 5μg anti-ETS2 (sc-351, Santa Cruz
Biotechnology) or 5μg of rabbit anti-mouse IgG (Dako) as a
background control. Samples were then incubated with blocked
GammaBind G Sepharose Beads (GE Healthcare Life Sciences,
Freiburg, Germany) and eluted in elution buffer (0.1M NaHCO3,
1% SDS). Untreated chromatin was used as input. Purified DNA
was used in qPCR reactions for analysis. All primers are listed in
Table S4 in Supplementary Material.
Results
miRNAs are Globally Deregulated in Aggressive
vs. Non-Aggressive PRL Tumors
In 12 PRL tumors classified according to the new classification
(7) and split into two groups (9): aggressive tumors (n= 4) and
non-aggressive tumors (n= 8) (Table 1, tumors in bold), miRNA
expression levels were assessed using Human miRNAMicroarray
V3 (Agilent Technologies) and analyzed with GeneSpring Soft-
ware 7.0. Signature comparison revealed a down-regulation of
11 miRNAs in aggressive compared to non-aggressive tumors
(Table 2). A technical validation of microarrays was performed
using TaqMan Low Density Assay (TLDA, Applied Biosystems)
on the same samples and 9 of the 11 miRNAs interrogated by the
TLDA assays presented the same changes in expression (Table 2).
miR-183 Appeared as a Main miRNA Involved in
Progression Toward Aggressiveness and
Malignancy
Previous transcriptomic analysis using Codelink microarrays had
been performed on 12 out of the 26 PRL tumors (Table 1,
tumors with *) and had revealed the deregulation of specific
genes involved in the control of cell cycle and proliferation and
interconnected in a pathway specifically up-regulated in aggres-
sive tumors (6, 9). This increased proliferation specifically in
aggressive tumors is consistent with the clinical data, the Ki-67
and p53 labeling and the classification recently proposed (7). For
the purpose of simplification, herein, we will refer to this pathway
as the “aggressive pathway” (Figure 1).
In order to identify miRNA potentially involved in tumoral
progression toward aggressive and malignant phenotype, we used
the following criteria: (1) miRNA targets (predicted by databases
and already published targets) should be linked to the “aggres-
sive pathway”; (2) targets mRNA expression should be inversely
correlated to miRNA expression at mRNA level; (3) significant
correlation should be observed between miRNA expression and
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TABLE 2 | Deregulated miRNA in aggressive vs. non-aggressive tumors.
Name Accessiona Chromosome Position Strand Cytoband Agilent microarrays TLDA assays
FCb p-Valuec FCb p-Valuec
hsa-miR-183 MI0000273 7 129414745-129414854 [ ] q32.2  2.74 0.018  2.23 0.0134
hsa-miR-148a MI0000253 7 25989539-25989606 [ ] p15.2  2.56 0.030  2.46 0.0444
hsa-miR-375 MI0000783 2 219866367-219866430 [ ] q35  2.39 0.013  2.01 0.0233
hsa-miR-342-3p MI0000805 14 100575992-100576090 [+] q32.2  2.07 0.050  2.74 0.0424
hsa-miR-23b MI0000439 9 97847490-97847586 [+] q22.32  1.95 0.032  1.83 0.0091
hsa-miR-744 MI0005559 17 11985216-11985313 [+] p12  1.93 0.015  2.93 0.0009
hsa-miR-98 MI0000100 X 53583184-53583302 [ ] p11.22  1.92 0.028  1.72 0.048
hsa-miR-340* MI0000802 5 179442303-179442397 [ ] q35.3  1.86 0.015 No probe
hsa-miR-574-3p MI0003581 4 38869653-38869748 [+] p14  1.84 0.047  2.12 0.0337
hsa-miR-331-3p MI0000812 12 95702196-95702289 [+] q22  1.83 0.012  1.87 0.0143
hsa-miR-1280 MI0006437 3 128081008-128081101 [+] q21.3  1.57 0.035 No probe
aAccession number from MirBase.
bFC, fold change of miRNA expression in A tumors compared to NA tumors.
cp-Value from Student’s test.
FIGURE 1 | The “aggressive pathway.” Up-regulated genes (red) and
downregulated genes (blue) are interconnected in a pathway involved in cell
cycle control. MiRNAs and their predicted targets are linked by bold lines. The
demonstrated targets are linked by solid lines, whereas predicted ones are
linked by dotted lines. The genes HTATIP2, DGKZ, CD44, TSG101, and
GTF2H1 are downregulated because of an allelic loss (chr11p region) (9).
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the main molecular markers of cell cycle taking into account in
the tumor grading (i.e., Ki-67 and p53).
Two databases (TargetScan and microRNA.org) were used in
order to identify known and predicted targets of the 11 deregu-
lated miRNA and lead to the identification of 541 mRNA targets.
Among these, only 22 genes presented a variation of expres-
sion in aggressive vs. non-aggressive tumors that was inversely
correlated to their associated miRNA. Using Ingenuity Pathway
Analysis Software on these 22 genes, we found that nine of
these genes were linked to the “aggressive pathway” and were
predicted to be regulated by four miRNAs (miR-183, miR-340*,
miR98, and miR-744) (Table 3). Finally, we assessed the cor-
relation between the four miRNA expression and Ki-67 and
p53 labeling in the 26 PRL tumors and it appeared that only
miR-183 showed a significant inverse correlation with both cell
cycle markers (miR-183:Ki-67 r= 0.58, p= 0.002; miR-183:p53
r= 0.59; p= 0.0014) (Table 3). Thus, we focused our atten-
tion on miR-183 that is down-regulated in aggressive vs. non-
aggressive tumors and its predicted targetKIAA0101 that is signif-
icantly up-regulated in aggressive vs. non-aggressive PRL tumors
(Figure 2). Finally, KIAA0101 expression was also significantly
correlated with Ki-67 (r= 0.58; p= 0.0018) and p53 (r= 0.53;
p= 0.0054).
miR-183 Regulates KIAA0101 by
Direct Interaction with 30-UTR
In order to verify miR-183 truly regulate its predicted target,
we over-expressed this miRNAs using pre-miR miRNA precur-
sors in HeLa and ZR-75-1 cell lines and measured the effect
on the expression levels of the predicted target by RT-qPCR.
These cell lines were used because the miRNAs of interest
are expressed at very low levels endogenously and present two
different proliferation rates (very high with HeLa cells and
low with ZR-75-1). Post-transcriptional regulation of KIAA0101
expression by miR-183 was assessed in vitro by monitoring
KIAA0101 mRNA and protein levels in HeLa and ZR-75-1 cell
lines 48 h after transfection of pre-miRNA-183. First, we con-
firmed that transfection of pre-miRNA-183 leads to a strong
and significant overexpression of mature miR-183 using TaqMan
microRNA Assay (Figure 3A). Following miR-183 overexpres-
sion, we observed a strong decrease in KIAA0101 mRNA and
protein levels in both cell lines (Figure 3A). The miR-183 was
found to inhibitKIAA0101 expression by directly interacting with
mRNA 30-UTR as shown by luciferase-reporter assay. Moreover,
the specificity of miR-183 binding was assessed using a mutation
in the sequence of KIAA0101 that is bound by miR-183 seed
(Figure 3B).
miR-183 Overexpression Decreases
Cell Proliferation
The criteria used to identify candidate miRNAs involved in
aggressiveness were strongly linked to proliferation as it is the
main difference between non-aggressive and aggressive PRL
tumors. Thus, we assessed the effect of miR-183 overexpression
on HeLa and ZR-75-1 cell lines. We performed growth curves on
three independent experiments overexpressing miR-183 in each
cell line. As shown in Figure 4A, miR-183 overexpression in HeLa
and ZR-75-1 cell lines led to a significant slowdown in cell growth.
Moreover, evaluation of the distribution of cell cycle phases at
120 h aftermiR-183 overexpression, using FACS analysis with pro-
pidium iodide labeling, showed that S phase tended to be delayed,
which could explain the decrease of proliferation rate (Figure 4B),
this was confirmed by a BrdU incorporation assay (data not
shown). These results strongly suggest the involvement of miR-
183 loss in control of proliferation and thus in the progression
toward aggressive phenotype.
miR-183 Expression is Controlled by the
Transcription Factor ETS2
The main mechanisms revealed to date underlying the deregu-
lation of miRNA expression in cancers are changes in chromo-
some copy number or DNA methylation (32). The analysis of
TABLE 3 | Predicted target of deregulated miRNA with inverse correlation in expression level.
miRNA
name
Accessiona FCb p-Valuec Gene
name
RefSeq FCd p-Valuec Correlatione
miRNA:mRNA
(r; p)
Correlationf
miRNA:Ki-67%
(r; p)
Correlationf
miRNA:P53%
(r; p)
miR-183 MI0000273  2.74 0.018 KIAA0101 NM_014736.4 3.071 0.0002  0.87; 0.0001  0.58; 0.002  0.59; 0.0014
miR-340* MI0000802  1.86 0.015 NEK2 NM_002497.2 16.340 0.0077  0.53; 0.0475  0.24; ns  0.19; ns
miR-98 MI0000100  1.92 0.028 AURKB NM_004217.2 5.022 0.0002  0.75; 0.0042  0.38; 0.0263  0.19; ns
CCNB2 NM_004701.2 2.278 0.0084  0.76; 0.0032
CENPK NM_022145.3 2.468 0.0009  0.89; 0.0001
UBE2T NM_014176.3 3.810 0.0236  0.53; 0.0478
E2F2 NM_177733.6 3.043 0.0076  0.56; 0.0340
miR-744 MI0005559  1.93 0.015 TGFB1 NM_000660.4 2.640 0.0079  0.55; 0.0408  0.31; ns  0.31; ns
In miRNA name * stands for “minor miRNA” meaning the miRNA originating for the preferentially degraded strand.
aAccession number from Mirbase.
bFC, fold change of miRNA expression in A tumors compared to NA tumors (26 tumors).
cp-Value from Student’s test comparing A vs. NA tumors.
dFold change of gene expression in A vs. NA tumors (26 tumors).
eCorrelation coefficient calculated between miRNA expression and their target gene (miRNA:mRNA) using Pearson test. Coefficient (r) and p-value (p) are given in that for each couple.
fCorrelation coefficient calculated between miRNA expression and Ki-67% (miRNA:Ki67%) or P53% (miRNA:P53%) using Spearman test. Coefficient (r) and p-value (p) are given in that
for each couple.
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FIGURE 2 | Expression of miR-183 and its predicted target KIAA0101
in human PRL tumors. Relative expression of miR-183 and KIAA0101
target gene was assessed by RT-qPCR in aggressive (A; n= 8) and
non-aggressive (NA; n= 18) human PRL tumors. Statistical relevance was
tested using unpaired t-test. *p<0.05; **p<0.005; ***p<0.0001.
these mechanisms in PRL tumors showed no significant differ-
ences between aggressive and non-aggressive tumors for miR183
miRNAanalyzed (data not shown).We therefore decided to search
for a transcription factor that could potentially be involved in
regulating the expression of this miRNA. Computational analy-
sis of miR-183 regulatory region using PROMO algorithm (33,
34) showed that 60 transcription factors could potentially regu-
late miR-183 (Table S4 in Supplementary Material). Correlations
between the expression of transcription factors and miRNA were
calculated using Spearman test and only ETS2:miR183 (r= 0.43,
p= 0.0167) showed significant correlation in the pituitary tumors
studied, moreover, ETS2 showed a significant down-regulation at
the mRNA level in the aggressive tumors compared to the non-
aggressive ones (Figure 5A; Table S4 in Supplementary Mate-
rial). We then tested the effect of overexpressing ETS2 in HeLa
and ZR-75-1 cell lines on miR-183 and its target KIAA0101. As
shown in Figure 5B, overexpression of ETS2 in both cell lines
significantly increased miR-183 expression. Moreover, exogenous
expression of ETS2 led to a decrease of KIAA0101 at the protein
level potentially through the observed increase in expression of
miR-183. Finally, chromatin immunoprecipitation experiments
revealed that ETS2 directly regulates miR-183 expression by bind-
ing its regulatory regions (Figure 5C). All these results seemed
to show that ETS2 is involved in the regulation of miR-183 and
that its down-regulation in aggressive PRL tumors could explain,
at least in part, the decrease of miR-183 expression.
Discussion
This study explores the role of miRNA in the progression of
26 PRL tumors with different behaviors, including 3 carcinomas
and attempts to characterize the hierarchical molecular events
leading to malignancy by integrating miRNA signatures with
previously obtained transcriptomic and genotyping data from the
same tumor samples. To reduce the complexity of the analysis,
we chose to focus on genes connected to a signaling pathway
that we have previously highlighted as up regulated in aggressive
PRL tumors (8, 9). While various studies on miRNAs have com-
paredmiRNAderegulation between normal and tumoral pituitary
tissues (Data S1 in Supplementary Material) thus highlighting
miRNA involvement in pituitary tumorigenesis, to our knowl-
edge, only one other study has investigated miRNA in tumoral
progression by comparing the differences between adenomas and
carcinomas in ACTH pituitary tumors (21). To assess the role of
miRNA deregulation in the progression of PRL tumors, we per-
formed the first global miRNA expression analysis in aggressive
and non-aggressive PRL tumors. Eleven miRNAs were identi-
fied as significantly deregulated between the two tumor groups.
Some of these deregulated miRNA have been described in studies
on pituitary tumorigenesis (tumoral vs. normal pituitary tissues)
(Table S1 in Supplementary Material). For example, miR-98 and
miR-23b are involved in tumorigenesis of pituitary tumors and
are down-regulated in GH tumors compared to normal pitu-
itary samples and can directly inhibit HMGA2 expression (35).
Up-regulation of the HMGA2 gene has a critical role in pitu-
itary tumorigenesis (24, 25, 29, 36–38). Interestingly, while no
change inHMGA2 expression has been observed between aggres-
sive and non-aggressive PRL tumors, comparison with normal
pituitary showed a significant increase in HMGA2 mRNA lev-
els, consistent with a decrease in miR-23b and miR-98 expres-
sion (data not shown). Similarly, miR-744 was down-regulated
in macro GH-adenomas vs. micro GH-adenomas, suggesting an
anti-tumoral role for this miRNA in GH pituitary tumors (20).
Among the predicted targets of the deregulated miRNAs, E2F2
and TGFβ1 have already been shown to be regulated by miR-
98 and miR-744, respectively (39, 40). E2F2 is involved in the
control of the G1/S phase transition and S phase progression
and its overexpression has been described in many cancers, in
which it is thought to promote cell proliferation (41). Moreover,
the E2F family, and especially E2F1, is overexpressed in GH
adenomas (24). Interestingly, E2F2 overexpression, in contrast
to E2F1, does not activate replicative senescence pathways (42,
43). The TGFβ1 pathway was described to be decreased during
pituitary tumorigenesis, especially in non-functioning adenoma,
suggesting a tumor suppressor role for this gene (22). Neverthe-
less, a role is emerging for TGF-beta in driving tumoral progres-
sion through differentmechanisms that favor immunosuppressive
activity, pro-angiogenic effects, and epithelial-to-mesenchymal
transition, the latter of which is important in the development of
metastasis (44). Consequently, it would be interesting to explore
the role of TGFB1 in PRL pituitary tumor aggressiveness and
malignancy.
In order to identify candidate miRNAs involved in progres-
sion to aggressiveness and malignancy, we used criteria based
on the main differences between aggressive and non-aggressive
PRL pituitary tumors, which are linked to proliferation. Indeed,
pathological classification showed that invasion and cell cycle
markers (Ki-67, p53, and mitosis) are able to discriminate tumor
grade and to predict tumor behavior (7). Moreover, we have
previously described genes over-expressed in aggressive as com-
pared to non-aggressive tumors that have a diagnostic and/or
prognostic ability (5, 6). Using these criteria, we highlight that
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FIGURE 3 |miR-183 directly regulates KIAA0101 expression by
binding to the 30-UTR. (A) miR-183 and KIAA0101 expression levels were
assessed by RT-QPCR. Transfection of pre-miR-183 precursor led to a
strong increase in miR-183 expression in HeLa and ZR-75-1 cell lines
compared to negative control miRNA precursor transfection. Consequently,
KIAA0101 expression was strongly decreased in both cell lines transfected
with pre-miR-183 precursor compared to negative control. KIAA0101 protein
level decreased in both cell lines overexpressing miR-183 compared to
negative control (scramble) transfected cells. (B) Predicted binding site of
miR-183 in KIAA0101 30 UTR was cloned 30 of the luciferase sequence
(match sequence). As a negative control, a mismatch sequence is the seed
was cloned 30 of the luciferase gene. Moreover normal luciferase was also
used. The luciferase assay clearly showed that luciferase activity is
decreased only when miR-183 is overexpressed in the presence of match
sequence. Statistical relevance was assessed using t-test *p<0.05;
**p<0.005; ***p<0.0001.
miR-183 is significantly down-regulated in aggressive vs. non-
aggressive tumors. Interestingly, miR-183 has been found to be
down-regulated in neuroblastoma (45), pancreatic cancer (46),
lung cancer (47, 48), ovarian cancer (49), and osteosarcoma
(50, 51) when compared to corresponding normal tissues. It has
been shown in several studies that overexpression of miR-183 in
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FIGURE 4 |miR-183 overexpression induces cell accumulation in
S phase thus decreasing cell proliferation. (A) HeLa and ZR-75-1 cell lines
overexpressing miR-183 showed a significant decrease in cell proliferation
compared to scramble control transfected cells. Growth curves were performed
by counting viable cells after miR-183 or scramble control transfection every day
for 5 days. (B) HeLa and ZR-75-1 cell lines overexpressing miR-183 seemed to
get trapped in S-phase of the cycle when compared to scramble control
transfected cells. Cell cycle analysis was performed by propidium iodide staining
of cells 120h after miR-183 or scramble control transfection. Stained cells were
analyzed on the LSRII FACS System to assess cell cycle phases. Experiments
were performed in triplicate. Statistical relevance was assessed using t-test
*p<0.05; **p<0.005; ***p<0.0001.
corresponding cell lines inhibits cell growth (47, 49, 51). These
data are consistent with our study corroborating the decrease
in cell proliferation of HeLa and ZR-75-1 cells after transfec-
tion with miR-183. As the oncogenic or tumor suppressor role
of miRNA depends on the messenger RNA they target, we
applied an integrative approach combining data onmiRNA global
expression with those obtained previously by target prediction
algorithms and transcriptomic analysis on the same human PRL
tumors. Our integrative analysis has identified KIAA0101 as a
new putative target for miR-183. In vitro, we show that miR-
183 decreases the expression of KIAA0101 at both the mRNA
and protein levels by directly binding to the 30-UTR. KIAA0101
is overexpressed in aggressive vs. non-aggressive PRL tumors,
and moreover, KIAA0101 expression is significantly correlated
with Ki-67 and p53 labeling. This is consistent with previous
studies showing that KIAA0101 overexpression is often corre-
lated with tumoral grade and lower survival in hepatocellular
carcinoma (52), human non-small cell lung cancer (53), adreno-
cortical tumors (54), gastric cancer (55), and breast cancer (56).
Inhibition of KIAA0101 by shRNA leads to a strong inhibition of
cell proliferation and particularly inhibition of S-phase progres-
sion (57). Consistent with these findings, we demonstrate that
miR-183-mediated KIAA0101 silencing decreases HeLa and ZR-
75-1 proliferation by deregulating cell cycle progression. Finally,
it is interesting to note that KIAA0101 is involved in the inhibi-
tion of p53-p21 cell cycle arrest/replicative senescence activating
pathways (55, 58, 59). Thus, the increase in KIAA0101 expression
in aggressive and malignant tumors is consistent with the model
of pituitary tumor progression proposed byMelmed, which posits
that an inhibition of replicative senescence is necessary for tumor
progression (60).
To explain the decrease in miR-183 expression in aggressive
PRL tumors, we first analyzed genetic alterations andDNAmethy-
lation in regulatory region but could not detect any differences
between aggressive and non-aggressive tumors at this locus (data
not shown). We then analyzed the deregulation of transcriptional
activators of miR-183. Among all of the transcription factors
with potential involvement in the regulation of miR-183, only
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FIGURE 5 | The transcription factor ETS2 regulates miR-183 expression.
(A) ETS2 relative expression was assessed in 20 non-aggressive and 6
aggressive human PRL tumors by RT-qPCR and a correlation graph was made
between miR-183 and ETS2 expression levels. (B) HeLa and ZR-75-1 cell lines
overexpressing ETS2 showed an increased miR-183 expression compared to
scramble control transfected cells. Moreover, in ZR-75-1 cells expressing ETS2,
KIAA0101 was decreased at the protein level as compared to scramble control
transfected cell. (C) ChIP assays using antibody directed against ETS2 showed
a significant enrichment of ETS2 binding sites in the miR-183 regulatory regions
(R1–R4) by qPCR compared to background control. Regions containing no
ETS2 binding sites (R0) showed no enrichment. Statistical relevance was
assessed using t-test *p<0.05; **p<0.005; ***p<0.0001.
ETS2 expression correlates with miR-183 expression. Indeed, we
demonstrate in this study that ETS2 activates miR-183 expression
by directly binding its regulatory regions. The role of ETS2 in
tumoral progression is controversial. Nevertheless, it has been
shown that KO-ETS2 in intestinal stem cells increases colonic
tumor frequency (61). Moreover, ETS2 overexpression activates
p53-dependent apoptosis in the context of Down’s syndrome (62).
Finally, in the context of pituitary adenoma, ETS2 is involved in
inhibition of PRL gene expression (63), and therefore, the decrease
of ETS2 mRNA in PRL tumors is consistent with the observed
hyperprolactinemia. In agreement with these data, we found ETS2
to be down-regulated in aggressive vs. non-aggressive human
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FIGURE 6 |Model of PRL tumoral progression toward an aggressive
phenotype. N, normal cell; P1–3, predisposed cells 1–3; NA, non-aggressive
tumors; A, aggressive tumors; M, malignant tumors (carcinomas). As described
in the main text, miRNA down regulation induces a specific progression toward
a malignant phenotype involving secondary genetic alterations, whereas
absence of miRNA deregulation leads to a non-aggressive phenotype.
PRL tumors. Together, these data suggest a role for ETS2 down-
regulation in the decreased miR-183 expression observed in the
same tumors.
In conclusion, integration of the miRNA signature with
transcriptomic profiling and clinical–pathological features has
allowed us to identify one miRNA and its new target which are
strongly involved in PRL tumor progression toward aggressive-
ness and malignancy. In combination with our previous studies,
we propose that the down-regulation of specific miRNAs such
as miR-183, perhaps through the inhibition of transcription acti-
vators, leads to the overexpression of some key genes connected
in the “aggressive pathway” that is specifically up regulated in
aggressive tumors. This deregulation of the cell cyclewould induce
an uncontrolled proliferation that allows the acquisition of advan-
tageous alterations, such as the loss of chromosome 11p, observed
specifically in aggressive and malignant PRL tumors (9). This
chromosomal alteration would in turn impact the expression of
key genes leading to the over-activation of cell proliferation and
acquisition of supplementary alterations specific to the malignant
phenotype (Figure 6). Finally, we demonstrated that integrative
genomic strategy applied in the same human tumors can iden-
tify candidate genes and the associated molecular mechanisms
responsible for tumor progression, even from a small cohort of
patients.
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